Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer

Peter Hoskin; Ana Rojas; Peter Ostler; Robert Hughes; Roberto Alonzi; Gerry Lowe

doi:10.1016/j.radonc.2017.06.014

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer

Peter Hoskin
, Ana Rojas
, Peter Ostler
, Robert Hughes
, Roberto Alonzi
, Gerry Lowe

Division of Cancer Sciences (L5)

Mount Vernon Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer.

PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS).

RESULTS: Median follow-up is 49, 63 and 108months (A, B and C, respectively). At 4years biochemical relapse free survival was 94% (A), 93% (B) and 91% (C) (p=0.54). Risk-category was the only significant independent predictor of relapse (p<0.0001). Kaplan-Meier 4-year-estimates of GU-3 were 2% (A and B) and 11% (C). GI-3 was 0% (A and B) and 1% (C). No GU or GI grade-4 events were observed. IPSS≥20 was 11% (A), 9% (B) and 16% (C) (p=0.9). Prevalence of GU-3 was ≤4% in the 3 groups at all times; GI-3 was low or non-existent. Prevalence of catheter use was ≤6% in all groups.

CONCLUSIONS: A single dose of 19-20Gy achieves similar rates of late morbidity and biochemical control compared to 2 and 3 fractions.

Original language	English
Pages (from-to)	56-60
Number of pages	5
Journal	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume	124
Issue number	1
DOIs	https://doi.org/10.1016/j.radonc.2017.06.014
Publication status	Published - Jul 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Aged
Aged, 80 and over
Brachytherapy/adverse effects
Humans
Kallikreins/blood
Male
Middle Aged
Neoplasm Recurrence, Local/blood
Prospective Studies
Prostate-Specific Antigen/blood
Prostatic Neoplasms/blood

Research Highlights, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1016/j.radonc.2017.06.014

Cite this

@article{44256c52ee214e8d84031741e485897d,

title = "Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer",

abstract = "BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer.PATIENTS AND METHODS: 293 patients received 1{\texttimes}19Gy or 1{\texttimes}20Gy (A=49), 2{\texttimes}13Gy (B=138), or 3{\texttimes}10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS).RESULTS: Median follow-up is 49, 63 and 108months (A, B and C, respectively). At 4years biochemical relapse free survival was 94\% (A), 93\% (B) and 91\% (C) (p=0.54). Risk-category was the only significant independent predictor of relapse (p<0.0001). Kaplan-Meier 4-year-estimates of GU-3 were 2\% (A and B) and 11\% (C). GI-3 was 0\% (A and B) and 1\% (C). No GU or GI grade-4 events were observed. IPSS≥20 was 11\% (A), 9\% (B) and 16\% (C) (p=0.9). Prevalence of GU-3 was ≤4\% in the 3 groups at all times; GI-3 was low or non-existent. Prevalence of catheter use was ≤6\% in all groups.CONCLUSIONS: A single dose of 19-20Gy achieves similar rates of late morbidity and biochemical control compared to 2 and 3 fractions.",

keywords = "Aged, Aged, 80 and over, Brachytherapy/adverse effects, Humans, Kallikreins/blood, Male, Middle Aged, Neoplasm Recurrence, Local/blood, Prospective Studies, Prostate-Specific Antigen/blood, Prostatic Neoplasms/blood",

author = "Peter Hoskin and Ana Rojas and Peter Ostler and Robert Hughes and Roberto Alonzi and Gerry Lowe",

year = "2017",

month = jul,

doi = "10.1016/j.radonc.2017.06.014",

language = "English",

volume = "124",

pages = "56--60",

journal = "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",

issn = "0167-8140",

publisher = "Elsevier BV",

number = "1",

}

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. / Hoskin, Peter; Rojas, Ana; Ostler, Peter et al.
In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 124, No. 1, 07.2017, p. 56-60.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer

AU - Hoskin, Peter

AU - Rojas, Ana

AU - Ostler, Peter

AU - Hughes, Robert

AU - Alonzi, Roberto

AU - Lowe, Gerry

PY - 2017/7

Y1 - 2017/7

N2 - BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer.PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS).RESULTS: Median follow-up is 49, 63 and 108months (A, B and C, respectively). At 4years biochemical relapse free survival was 94% (A), 93% (B) and 91% (C) (p=0.54). Risk-category was the only significant independent predictor of relapse (p<0.0001). Kaplan-Meier 4-year-estimates of GU-3 were 2% (A and B) and 11% (C). GI-3 was 0% (A and B) and 1% (C). No GU or GI grade-4 events were observed. IPSS≥20 was 11% (A), 9% (B) and 16% (C) (p=0.9). Prevalence of GU-3 was ≤4% in the 3 groups at all times; GI-3 was low or non-existent. Prevalence of catheter use was ≤6% in all groups.CONCLUSIONS: A single dose of 19-20Gy achieves similar rates of late morbidity and biochemical control compared to 2 and 3 fractions.

AB - BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer.PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS).RESULTS: Median follow-up is 49, 63 and 108months (A, B and C, respectively). At 4years biochemical relapse free survival was 94% (A), 93% (B) and 91% (C) (p=0.54). Risk-category was the only significant independent predictor of relapse (p<0.0001). Kaplan-Meier 4-year-estimates of GU-3 were 2% (A and B) and 11% (C). GI-3 was 0% (A and B) and 1% (C). No GU or GI grade-4 events were observed. IPSS≥20 was 11% (A), 9% (B) and 16% (C) (p=0.9). Prevalence of GU-3 was ≤4% in the 3 groups at all times; GI-3 was low or non-existent. Prevalence of catheter use was ≤6% in all groups.CONCLUSIONS: A single dose of 19-20Gy achieves similar rates of late morbidity and biochemical control compared to 2 and 3 fractions.

KW - Aged

KW - Aged, 80 and over

KW - Brachytherapy/adverse effects

KW - Humans

KW - Kallikreins/blood

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local/blood

KW - Prospective Studies

KW - Prostate-Specific Antigen/blood

KW - Prostatic Neoplasms/blood

UR - https://www.scopus.com/pages/publications/85021749639

U2 - 10.1016/j.radonc.2017.06.014

DO - 10.1016/j.radonc.2017.06.014

M3 - Article

C2 - 28666552

SN - 0167-8140

VL - 124

SP - 56

EP - 60

JO - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

IS - 1

ER -

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer

Abstract

UN SDGs

Keywords

Research Highlights, Institutes and Platforms

Access to Document

Other files and links

Fingerprint

Cite this